eCTD Submission Strategies: In-house vs. Outsourcing

Webinar: eCTD Submission Different Strategies: In-house vs. Outsourcing

eCTD Submission Strategies, including outsourcing, are influenced by varying requirements in various regions and countries. That and diverse technical resources by companies often lead to various regulatory strategies. Thus, the questions arises: how to choose the best tactics for eCTD submission that your needs?

The purpose of this webinar is to discuss the different approaches to prepare eCTD submissions, its requirements, technical resources, and process validation.

 

You will learn about:

1. Requirements for eCTD

  • Different forms of eCTD used in EU vs. EAEU eCTD
  • Legislation framework
  • Regions and countries following the eCTD

2. Different approaches to prepare eCTD submissions: In-house vs. Outsourcing

3. Technical resources

  • Software and networks
  • Document and project management
  • Potential challenges

4. How to validate submission to achieve compliance and high quality

  • Tips and tricks

 

Registering a new product?

Make use of our experts to enter new markets. Explore your options in an informal chat with one of our experts.

Who Should Attend? Professionals from the following fields:

  • Regulatory Managers
  • Regulatory Strategy Managers
  • RA Partnerships Operations Manager
  • QA Managers supporting RA
  • RA Healthcare Compliance Managers

 

Duration: 25 min.

Speaker: Head of Global Regulatory Affairs, Olga Bernardova, MSc, who will share her expertise regarding eCTD submissions.

Olga Bernardova, MSc

Olga Bernardova, MSc

Head of Global Regulatory Affairs

Other content that might interest you:

CMC: Effective Writing of IND and IMPD

CMC: Effective Writing of IND and IMPD

Do we truly know how to ensure IND or IMPD Quality (CMC) part is written in good quality, consistent and clear technical language? How to effectively manage the writing process? In this article, I will focus on these questions and the initial IND/IMPD, required to start clinical investigations in humans. Furthermore, I will provide the key features and practical advice on how to deliver effectiveness. Firstly, we have to define the team in order to understand if the organization has capabilities to do CMC writing in-house or needs to outsource.

read more
Biomapas appoints Head of Global Regulatory Affairs

Biomapas appoints Head of Global Regulatory Affairs

May 2020 – Olga Bernardova joins Biomapas as Head of Global Regulatory Affairs to lead the regulatory affairs department and to ensure the best processes and means to serve Biomapas growth and international expansion. As a functional and full outsourcing solution provider, with offices in Lithuania, Switzerland, Sweden, Russia, Georgia, Ukraine, Poland and Kazakhstan, Biomapas continues to expand its international team and further increases capabilities for client-oriented solutions.

read more
Regulatory Documents Translation Process – How to Ensure Consistency and Correctness

Regulatory Documents Translation Process – How to Ensure Consistency and Correctness

Mistranslation of regulatory documents such as a summary of product characteristics, product information leaflets and instructions for use, could have a negative impact for the company and most importantly could lead to serious consequences to a patient’s health. In 2007, as a result of inaccurate translation, 47 patients had badly implanted knee prostheses. An outer package labelled in English included different information.

read more
Remaining Vigilant and Compliant after Brexit: What’s next? (Latest Updates)

Remaining Vigilant and Compliant after Brexit: What’s next? (Latest Updates)

On 29th March 2017 UK submitted the notification of its intention to withdraw from the EU. This means that UK will become a ‘third country’ from 30th March’19. Even though leaving the EU with a deal remains the Government’s top priority, UK drug agency is publishing a series of guidance documents for industry and other stakeholders covering the proposed arrangements for the regulation of medicines, medical devices and clinical trials, if UK leaves EU with no deal.

read more
Tuberculosis Medicines Clinical Development in Eastern Europe and CIS

Tuberculosis Medicines Clinical Development in Eastern Europe and CIS

World Tuberculosis Day is commemorated every year on 24th March to raise awareness of tuberculosis, which is still causing death of nearly 1.5 million people each year, mostly in developing countries. It marks the day in 1882, when Dr. Robert Koch announced that he had discovered the cause of tuberculosis, the TB bacillus. In comparison to other infectious diseases caused by a single infectious agent, tuberculosis is the second biggest killer worldwide.

read more
AICROS Annual Meeting: insights and future perspectives

AICROS Annual Meeting: insights and future perspectives

The Association of International Clinical Research Organizations (AICROS) is a network of small to mid-size CROs, which provide clinical research services to the pharmaceutical, biotech and medtech industries. Biomapas joined AICROS in 2014 and since then has been an active member of the association. On the 20-22 February, Biomapas’ CEO Audrius Sveikata participated in the AICROS Annual meeting, which took place in Tel Aviv, Israel. Audrius shared his insights about the meeting and the future perspectives of the association.

read more

Big Enough To Cover  All Your Needs. Small Enough To Care.

Discover the tailored solutions that Biomapas provides to accelerate your clinical trials and optimize your drug development process.

Clinical Research

Regulatory Affairs

Pharmacovigilance

Medical Information